SEC Form 4 · accession 0001609351-17-000094
Spark Therapeutics, Inc. · ONCE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen W Webster
Officer — Chief Financial Officer
Period of report
Aug 15, 2017
Accepted (ET)
Aug 15, 2017 · 5:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609351
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 15, 2017 | M | 10,000 | $3.45 | A | 12,500 | D | |
| Common StockF2 | Aug 15, 2017 | S | 10,000 | $79.38 | D | 2,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $3.45 | Aug 15, 2017 | M | 10,000 | D | — | Jul 7, 2024 | Common Stock | 10,000 | 116,015 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2017, as amended.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.20 to $79.67, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- F3This option was granted on July 7, 2014 and vests over four years, with 25% of the shares underlying the option vesting on July 7, 2015, and the remainder vesting quarterly thereafter.